HOME >> MEDICINE >> NEWS
Some Alzheimer's patients can benefit from drug memantine

The drug memantine can reduce cognitive deterioration and loss of everyday functions in patients with moderate to severe Alzheimer's disease, according to a new review of studies.

Memantine's effects are small but "clinically noticeable" after patients take 20 milligrams of the drug daily for 28 weeks, according to Dr. Rupert McShane of the University of Oxford and colleagues. The effect of memantine was measured by a variety of tests that rate a patient's thinking skills, daily activity and mood.

While there is no evidence that the drug can treat agitation in Alzheimer's patients, it does appear to prevent the onset of agitation, the review finds.

The studies also hint at some cognitive benefits from the drug for patients with mild to moderate Alzheimer's and vascular dementia, which occurs when brain cells are starved of oxygen by blocked or diseased blood vessels. However, these changes were not clinically significant, and it remains unknown whether there is a true benefit in mild to moderate cases, McShane and colleagues write.

The Food and Drug Administration approved memantine for the treatment of moderate to severe Alzheimer's dementia in 2003. The European Agency for the Evaluation of Medical Products approved the drug for similar indications in 2002. Manufacturers of the drug in Europe and the United States have applied for approval of the drug for mild to moderate Alzheimer's dementia.

The review appears in the April issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The review included nine published studies comprising 2,339 participants, but three important trials have not yet been published.

To account for the missing data, the Cochrane researchers als
'"/>

Contact: Rupert McShane
rupert.mcshane@psych.ox.ac.uk
Center for the Advancement of Health
19-Apr-2005


Page: 1 2

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Alzheimers disease to quadruple worldwide by 2050
3. Study outlines how stroke, head injury can increase risk of Alzheimers disease
4. Explaining a link between strokes and Alzheimers
5. MU researchers find mechanisms that may unlock answers to Alzheimers disease
6. Blocking stress protein decreases Alzheimers peptide in mice
7. Nursing home placement associated with accelerated cognitive decline in Alzheimers disease
8. Brain inflammation may be friend, not foe, for Alzheimers patients
9. Blood inflammation plays role in Alzheimers disease
10. Alzheimers weight gain initiative also improved patients intellectual abilities
11. Can an omega-3 fatty acid slow the progression of Alzheimers disease?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Some Alzheimer patients can benefit from drug memantine

(Date:7/28/2015)... ... 2015 , ... Carol McFarland, PT, PhD, OCS focuses entirely ... specific rehabilitation exercises and treatment protocols in the PTA OT PT Continuing ... interview conducted by Carol with a board certified neurosurgeon. Specific case studies are ...
(Date:7/28/2015)... SD (PRWEB) , ... July 28, 2015 , ... Peter Forbes, President of the Veterans ... of the Vietnam War Inc. and the Veterans Coalition, is spearheading a campaign to help ... , The UVBH teaches Veterans life and trade skills. Forbes and the UVBH assists and ...
(Date:7/27/2015)... ... July 28, 2015 , ... Conducting Advanced Root Cause Analysis ... the Quality of Investigations , **Presented by FDAnews and Learning Plus**, Sept. 16-17, ... been the #1 reason for 483 observations since 1997! , The FDA's enforcement ...
(Date:7/27/2015)... , ... July 28, 2015 , ... The National ... inductee into the NAPW VIP Woman of the Year Circle. She is recognized with ... 200 operating Local Chapters, NAPW is the nation’s leading networking organization exclusively for professional ...
(Date:7/27/2015)... ... July 27, 2015 , ... The FSH ... and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), today announced the introduction of the ... FSHD care guideline is published today. , This new guideline condenses the ...
Breaking Medicine News(10 mins):Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 3Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 4Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 5Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 6Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 2Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 4Health News:NAPW Inducts Jane Simmons, Counseling Intern at Omar Bradley Middle School of the Northeast Independent School District , Into its VIP Woman of the Year Circle 2Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2
(Date:7/27/2015)... HERTFORDSHIRE, England and PITTSBURGH , ... today announced that it will hold its extraordinary general meeting ... Company plc (NYSE: PRGO ; TASE) at the Okura ... Central European Time (CET). Among other agenda ... to vote on the approval, under article 2:107a of the ...
(Date:7/27/2015)... , July 27, 2015  QT Vascular Ltd., ... a global company engaged in the design, assembly and ... treatment of vascular disease, has entered into an agreement ... to US$13.14 million convertible bond investment. This funding will ... its growth to the next milestone. ...
(Date:7/27/2015)... WASHINGTON , July 27, 2015 Even ... Larkin , MD, FACP, NCMP, as scientific co-chair for ... health coalition to serve as an expert voice in ... treatment options for women struggling with Hypoactive Sexual Desire ... "I am honored to join Even ...
Breaking Medicine Technology:Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 2Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 3Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 4Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 5Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 6Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 8Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 9Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 10QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3Dr. Lisa Larkin Joins the Even the Score Coalition as Scientific Co-Chair 2Dr. Lisa Larkin Joins the Even the Score Coalition as Scientific Co-Chair 3
Cached News: